Health insurance and the growth in pharmaceutical expenditures

被引:28
作者
Danzon, PM [1 ]
Pauly, MV [1 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
关键词
D O I
10.1086/368005
中图分类号
F [经济];
学科分类号
02 ;
摘要
This paper examines the contribution of insurance coverage to the recent unprecedented growth in spending on pharmaceuticals. Trends in drug spending over time closely paralleled the growth in drug coverage. Most of the coverage growth reflects an increase in the number of people with coverage, 65 percent from 1987 to 1996, rather than increased depth of coverage. The direct moral hazard effect of this insurance growth accounts for between one-fourth and one-half of the increase in drug spending. Technological change contributed to these changes, because both the flow of new drugs increased the demand for insurance and information technologies enabled the development of pharmacy benefit management, which reduced the real price of drug coverage. It is plausible that insurance growth also stimulated drug promotion. The only obvious source of inefficiency is the tax subsidy, which may lead to excessive insurance and promotion. This applies to all health care, not just pharmaceuticals.
引用
收藏
页码:587 / 613
页数:27
相关论文
共 12 条
  • [1] The US pharmaceutical industry: Why major growth in times of cost containment?
    Berndt, ER
    [J]. HEALTH AFFAIRS, 2001, 20 (02) : 100 - 114
  • [2] *C BUDG OFF, 2002, ISS DES PRESCR DRUG
  • [3] Cohen JP, 2000, FOOD DRUG LAW J, V55, P311
  • [4] Insurance and new technology: From hospital to drugstore
    Danzon, PM
    Pauly, MV
    [J]. HEALTH AFFAIRS, 2001, 20 (05) : 86 - 100
  • [5] *DEP HLTH HUM SERV, 2000, REP PRES PRESCR DRUG
  • [6] Explaining drug spending trends: Does perception match reality?
    Dubois, RW
    Chawla, AJ
    Neslusan, CA
    Smith, MW
    Wade, S
    [J]. HEALTH AFFAIRS, 2000, 19 (02) : 231 - 239
  • [7] Financial incentives and drug spending in managed care
    Hillman, AL
    Pauly, MV
    Escarce, JL
    Ripley, K
    Gaynor, M
    Clouse, J
    Ross, R
    [J]. HEALTH AFFAIRS, 1999, 18 (02) : 189 - 200
  • [8] Kaitin KI, 2000, DRUG INF J, V34, P673, DOI 10.1177/009286150003400303
  • [9] The effect of managed care on prescription drug costs and benefits
    Lyles, A
    Palumbo, FB
    [J]. PHARMACOECONOMICS, 1999, 15 (02) : 129 - 140
  • [10] Pharmaceutical Research and Manufacturers of America, 2002, PHARM IND PROF 2002